Clinical Trial: NCT04189614
An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
Status:
TERMINATEDPhase:
Phase 1| Lead Sponsor: | AbbVie |
| Information Provided By: | AbbVie |
| Last Update Posted: | 2026-06-04 |
Study Overview
Brief Summary
This study is being done to determine the efficacy and safety of cofetuzumab pelidotin in the PTK7-expressing, recurrent non-small cell lung cancer (NSCLC) population.
Official Title
A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (ABBV-647, a PTK7-Targeting Antibody Drug Conjugate) in Subjects With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
Conditions
Cancer, Non-small Cell Lung Cancer (NSCLC)
Intervention / Treatment
- Drug: Cofetuzumab Pelidotin
Other Study ID Numbers
- M19-611
- 2019-003472-39
- 2019
Start Date (Actual)
2020-02-13
Primary Completion Date (Actual)
2026-05-07
Study Completion Date (Actual)
2026-05-07
Enrollment (Actual)
65
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | AbbVie |
| Information Provided By: | AbbVie |
| Last Update Posted: | 2026-06-04 |
Study Overview
Brief Summary
This study is being done to determine the efficacy and safety of cofetuzumab pelidotin in the PTK7-expressing, recurrent non-small cell lung cancer (NSCLC) population.
Official Title
A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (ABBV-647, a PTK7-Targeting Antibody Drug Conjugate) in Subjects With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
Conditions
Cancer, Non-small Cell Lung Cancer (NSCLC)
Intervention / Treatment
- Drug: Cofetuzumab Pelidotin
Other Study ID Numbers
- M19-611
- 2019-003472-39
- 2019
Start Date (Actual)
2020-02-13
Primary Completion Date (Actual)
2026-05-07
Study Completion Date (Actual)
2026-05-07
Enrollment (Actual)
65
Study Type
Interventional
Phase
Phase 1